Observed Signal · Sep 22, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive

Biolevate raises €30M Series A for life sciences AI

Executive Signal Summary

Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Notable funding round in the AI for life sciences sector, highlighting growing enterprise adoption of agentic AI platforms, though not directly impacting core AdTech.

SIGNAL RADAR

Track Dataiku Signals & Market Shifts in Real-Time

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • Biolevate raised €30 million in Series A funding.
  • The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and EQT Ventures.
  • Biolevate's platform can run up to 100,000 agents concurrently and has accelerated literature reviews 16-fold.
  • The company is opening a US office in Boston and has doubled headcount over the past year.
  • Biolevate has drafted seven patent applications, two filed in Europe.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Tech.eu (European Tech & Deals)•Published: Sep 22, 2026
Original Coverage Title: “Biolevate lands €30M Series A to scale life sciences AI”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

AI in Drug DevelopmentOct 27, 2026

Atlas Bio Raises $12.5M for AI Clinical Trial Simulations

Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.

Read assessment
FundingSep 17, 2026

Health Force Raises €4.2M for Hospital AI Agents

Barcelona-based Health Force, a HealthTech startup, raised €4.2 million in Seed funding to expand its enterprise-grade AI agents for hospital operations. The round was led by LUMO Labs with participation from Step Venture, Next Tier Ventures, Target Global, and Calm/Storm. Founded in 2022 in Vienna, Health Force automates administrative tasks in hospitals, such as prior-authorisation checks, claims processing, and regulatory reporting. The company reports that its AI agents handle 75% of cases autonomously and are deployed at leading Italian hospital groups, including Humanitas and Gruppo San Donato, processing over 200,000 patient cases annually. The company plans to use the funds to expand into new workflows and European markets including Germany, France, and Spain.

Read assessment
FundingNov 12, 2026

Orakl Oncology Raises €30M for AI Cancer Drug Prediction

Orakl Oncology, a French TechBio company, announced a €30 million ($34 million) Series A round co-led by Norrsken VC and Singular, with participation from InfraVia Capital Partners, Serena, Patient Autonome Fund managed by Bpifrance, Teampact Ventures, Plug and Play, and existing investors Verve Ventures VC, Speedinvest, and HCVC. The company uses AI and patient-derived tumor organoids to build 'virtual cancer patients' that predict drug performance in clinical trials, aiming to reduce the high failure rate in Phase 2 oncology trials. Orakl claims 90% accuracy in predicting clinical outcomes. The funding will expand its platform across more cancer types and geographies. Total funding now stands at €45 million.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for Dataiku & competitors in your briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime